Display options
Cite
Butti R, Kumar TV, Nimma R, et al. Impact of semaphorin expression on prognostic characteristics in breast cancer. Breast Cancer (Dove Med Press). 2018;10:79-88doi: 10.2147/BCTT.S135753.
Butti, R., Kumar, T. V., Nimma, R., & Kundu, G. C. (2018). Impact of semaphorin expression on prognostic characteristics in breast cancer. Breast cancer (Dove Medical Press), 1079-88. https://doi.org/10.2147/BCTT.S135753
Butti, Ramesh, et al. "Impact of semaphorin expression on prognostic characteristics in breast cancer." Breast cancer (Dove Medical Press) vol. 10 (2018): 79-88. doi: https://doi.org/10.2147/BCTT.S135753
Butti R, Kumar TV, Nimma R, Kundu GC. Impact of semaphorin expression on prognostic characteristics in breast cancer. Breast Cancer (Dove Med Press). 2018 May 31;10:79-88. doi: 10.2147/BCTT.S135753. eCollection 2018. PMID: 29910635; PMCID: PMC5987790.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer (Dove Med Press). 2018 May 31;10:79-88. doi: 10.2147/BCTT.S135753. eCollection 2018.

Impact of semaphorin expression on prognostic characteristics in breast cancer.

Breast cancer (Dove Medical Press)

Ramesh Butti, Totakura Vs Kumar, Ramakrishna Nimma, Gopal C Kundu

Affiliations

  1. Laboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science, Savitribai Phule Pune University, Pune, India.

PMID: 29910635 PMCID: PMC5987790 DOI: 10.2147/BCTT.S135753

Abstract

Breast cancer is one of the major causes of cancer-related deaths among women worldwide. Aberrant regulation of various growth factors, cytokines, and other proteins and their receptors in cancer cells drives the activation of various oncogenic signaling pathways that lead to cancer progression. Semaphorins are a class of proteins which are differentially expressed in various types of cancer including breast cancer. Earlier, these proteins were known to have a major function in the nerve cell adhesion, migration, and development of the central nervous system. However, their role in the regulation of several aspects of tumor progression has eventually emerged. There are over 30 genes encoding the semaphorins, which are divided into eight subclasses. It has been reported that some members of semaphorin classes are antiangiogenic and antimetastatic in nature, whereas others act as proangiogenic and prometastatic genes. Because of their differential expression and role in angiogenesis and metastasis, semaphorins emerged as one of the important prognostic factors for appraising breast cancer progression.

Keywords: angiogenesis; breast cancer; cancer stem-like cells; epithelial to mesenchymal transition; metastasis; neuropilins; plexins; prognostic factor; semaphorins; tumor microenvironment; vascular endothelial growth factor

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Neuron. 1997 Dec;19(6):1159-62 - PubMed
  2. Front Endocrinol (Lausanne). 2013 Sep 23;4:133 - PubMed
  3. Cell. 1999 May 28;97(5):551-2 - PubMed
  4. Cell. 1998 Mar 20;92(6):735-45 - PubMed
  5. Nature. 2010 Oct 28;467(7319):1118-22 - PubMed
  6. J Biol Chem. 2007 Sep 7;282(36):26294-305 - PubMed
  7. Exp Mol Pathol. 2015 Aug;99(1):19-24 - PubMed
  8. PLoS One. 2013 May 08;8(5):e61788 - PubMed
  9. Cell. 1999 Oct 1;99(1):71-80 - PubMed
  10. Oncogene. 2010 Aug 26;29(34):4741-51 - PubMed
  11. J Clin Invest. 2012 Apr;122(4):1296-305 - PubMed
  12. Curr Genomics. 2010 Nov;11(7):528-36 - PubMed
  13. Int J Clin Exp Pathol. 2015 Feb 01;8(2):1584-93 - PubMed
  14. Cell Signal. 2014 Dec;26(12):2843-56 - PubMed
  15. J Biol Chem. 2010 Jan 22;285(4):2463-73 - PubMed
  16. Anticancer Res. 2016 Mar;36(3):1281-6 - PubMed
  17. Mol Biol Cell. 2012 Oct;23(19):3873-81 - PubMed
  18. Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11432-7 - PubMed
  19. Blood. 2008 Mar 1;111(5):2674-80 - PubMed
  20. Int J Oncol. 2017 Nov;51(5):1395-1404 - PubMed
  21. Oncogene. 2013 Jan 31;32(5):544-53 - PubMed
  22. Histopathology. 2011 Aug;59(2):274-82 - PubMed
  23. Oncol Rep. 2015 Aug;34(2):1049-57 - PubMed
  24. Neoplasia. 2003 Jan-Feb;5(1):83-92 - PubMed
  25. Neuron. 1997 Sep;19(3):531-7 - PubMed
  26. Clin Cancer Res. 2017 Jan 1;23 (1):214-224 - PubMed
  27. PLoS One. 2016 Feb 24;11(2):e0150151 - PubMed
  28. J Exp Med. 2008 Jul 7;205(7):1673-85 - PubMed
  29. Science. 2004 Aug 6;305(5685):862-5 - PubMed
  30. EMBO J. 2007 Nov 28;26(23):4902-12 - PubMed
  31. Eur J Cancer. 2009 Feb;45(3):405-13 - PubMed
  32. J Cancer Res Clin Oncol. 2010 Jun;136(6):863-72 - PubMed
  33. Neuron. 2001 Feb;29(2):429-39 - PubMed
  34. Oncol Lett. 2017 Nov;14 (5):5913-5917 - PubMed
  35. Crit Rev Oncog. 2013;18(1-2):43-73 - PubMed
  36. Oncogene. 2016 Sep 29;35(39):5170-8 - PubMed
  37. Oncogene. 2017 Oct 5;36(40):5567-5575 - PubMed
  38. EMBO Rep. 2004 Jul;5(7):710-4 - PubMed
  39. J Cell Sci. 2009 Jun 1;122(Pt 11):1723-36 - PubMed
  40. Cell. 1993 Dec 31;75(7):1389-99 - PubMed
  41. Int J Breast Cancer. 2015;2015:539721 - PubMed
  42. Cancer Immunol Res. 2015 Jun;3(6):689-701 - PubMed
  43. Genome Biol. 2006;7(3):211 - PubMed
  44. Cancer Res. 2008 Oct 15;68(20):8295-303 - PubMed
  45. J Mol Biol. 2013 Nov 15;425(22):4405-14 - PubMed
  46. J Clin Invest. 2010 Aug;120(8):2684-98 - PubMed
  47. Cancer Res. 2015 Jun 1;75(11):2177-86 - PubMed
  48. Clin Cancer Res. 2007 Feb 15;13(4):1115-22 - PubMed
  49. Nat Rev Cancer. 2008 Aug;8(8):632-45 - PubMed
  50. Cancer Cell. 2013 Nov 11;24(5):673-85 - PubMed
  51. J Biol Chem. 2008 Jan 25;283(4):1893-901 - PubMed
  52. Cancer Cell. 2012 Aug 14;22(2):145-52 - PubMed
  53. Cancer Res. 2005 Jul 15;65(14):6167-77 - PubMed
  54. Biochem J. 2008 Apr 15;411(2):211-26 - PubMed
  55. J Neurosci. 2007 Jun 6;27(23):6333-47 - PubMed
  56. Genes Cells. 2004 Sep;9(9):821-9 - PubMed
  57. Int J Breast Cancer. 2017;2017:9619734 - PubMed
  58. Cell. 1997 Aug 22;90(4):739-51 - PubMed
  59. Expert Opin Ther Targets. 2015 Mar;19(3):427-42 - PubMed
  60. Proc Natl Acad Sci U S A. 2012 Feb 21;109 (8):2784-9 - PubMed
  61. Front Physiol. 2014 Feb 05;5:17 - PubMed
  62. Onco Targets Ther. 2016 Sep 26;9:5737-5750 - PubMed
  63. Cancer Res. 2012 Apr 1;72(7):1728-39 - PubMed
  64. Oncogene. 2015 Mar 19;34(12 ):1584-95 - PubMed
  65. Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):741-9 - PubMed
  66. Cell. 1999 Oct 1;99(1):59-69 - PubMed
  67. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  68. Curr Opin Struct Biol. 2004 Dec;14(6):669-78 - PubMed
  69. Breast Cancer Res Treat. 2009 Nov;118(1):197-205 - PubMed
  70. Cancer Cell. 2004 Jul;6(1):75-84 - PubMed
  71. J Clin Oncol. 2005 Mar 10;23(8):1782-90 - PubMed
  72. Mol Cancer. 2010 Sep 21;9:251 - PubMed
  73. Oncotarget. 2015 Feb 20;6(5):3268-79 - PubMed
  74. Trends Biochem Sci. 1999 Jul;24(7):261-3 - PubMed
  75. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 - PubMed
  76. Cancer Lett. 2017 Jul 1;397:12-22 - PubMed
  77. J Biol Chem. 2007 Mar 2;282(9):6899-905 - PubMed
  78. Oncotarget. 2015 Feb 28;6(6):3507-18 - PubMed

Publication Types